Please assess the completion status of the following clinical trial:

Trial Title: Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females ≥18 years of age.~2. Requirement for dental surgery for extraction of ≥2 third molars, at least 1 of which involves partial or complete mandibular bony impaction.~3. Pain Intensity (PI) using a Numeric Pain Rating Scale (NPRS) ≥5 during the 5 hours following the end of surgery in the eligibility assessment as well as in the baseline assessment immediately pre-dosing.~4. Rating of moderate or severe pain on a 4-point categorical pain rating scale (i.e., none, mild, moderate, severe) during the 5 hours following the end of surgery.~Exclusion Criteria:~1. Previously dosed with MR-107A-02.~2. Subject with known hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs).~3. Active GI bleeding or a history of peptic ulcer disease, active inflammatory bowel disease, e.g., Crohn's Disease or ulcerative colitis,or bleeding disorders that may affect coagulation.~4. Moderate or severe hypertension, prior stroke or transient ischemic attack.~5. Use of any investigational drug within 28 days, or 5 half-lives, prior to consent whichever is longer.~6. Use of medications with the potential to interact with MR-107A-02.~7. Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MR-107A-02 1.25 mg twice in a 24 hour period (Type: EXPERIMENTAL): Oral tablet, one day of dosing
- MR-107A-02 5 mg twice in a 24 hour period (Type: EXPERIMENTAL): Oral tablet, one day of dosing
- MR-107A-02 15 mg twice in a 24 hour period (Type: EXPERIMENTAL): Oral tablet, one day of dosing
- Placebo twice in a 24 hour period (Type: PLACEBO_COMPARATOR): Oral tablet, one day of dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).